VC: GlobeImmune leads with $34.3 million



GlobeImmune leads with $34.3 million second round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

GlobeImmune
Denver

$34.3 million
second round

Lilly Ventures

GlobeImmune is developing immunotherapy products called Tarmogens(TM) for the treatment of cancer and chronic infectious diseases.

Kereos
St. Louis

$19.5 million
second round

Prolog Ventures

Kereos is advancing its lead product candidates KI-0001, a targeted imaging agent to detect various solid tumors, and KI-1001, a targeted chemotherapeutic to selectively destroy tumors, through Phase I/II clinical trials.

Teranode Corporation
Seattle

$9.5 million
second round

Cargill Ventures and Trident Capital

Teranode develops software for the life sciences industry.

Caldera Pharmaceuticals
Los Alamos, NM

$7 million

Individuals

Caldera is developing a system that allows for faster testing of chemical samples against an array of proteins.

Chiasma
Jerusalem

$6.2 million
second round

F-2 Ventures and the Ofer Hi-Tech Group

Chiasma has been developing platform technology for the oral delivery of macromolecule drugs.

Athenagen
Menlo Park, CA

$5.69 million
first round

Sanderling Ventures

Athenagen is developing small-molecule drugs designed to either inhibit or enhance angiogenesis, based on the discovery of a new endothelial cell angiogenesis pathway.

Dimerix
Melbourne, Australia

Undisclosed
round one

Foundation Capital

Dimerix is striving to develop more effective drugs with fewer side-effects, by applying its technologies to novel G-Protein Coupled Receptor (GPCR) cluster targets.

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.